Radar · Life Sciences in Palo Alto
Best Life Sciences Companies in Palo Alto, United States
The 165 best Life Sciences companies in Palo Alto, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Medable.
By Riya SenguptaFinancials
165companies tracked
$4.7Bdisclosed funding
1unicorns
97have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × PALO ALTO
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
164companies analysed
83%cloud-native stacks
2025funding peak (by rounds)
7unicorns
2016median founding year
383kcombined LinkedIn audience
61%of audience held by top 3
2companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Palo Alto
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Medable 🦄 Provider of a cloud based clinical trail management tool for researchers | $521M | 56 mo ago | 376 376 → 359 (-5%) | 2012 | James Sas Co-Founder | 14 patents Digital health data integration, remote patient monitoring, and clinical trial management platforms | — |
| 2 | BridgeBio Developer of therapeutics for the treatment of genetic diseases | $434M | 25 mo ago | 383 | 2015 | Neil Kumar Co-Founder & CEO | 32 patents Targeted small‑molecule cancer combos (KRAS, EGFR, SHP2) and metabolic kidney disease therapies | 1 award |
| 3 | CardioDx Precision medicine: blood tests for coronary artery disease assessment | $282M | 113 mo ago | 99 | 2004 | — | 45 patents Molecular diagnostic biomarkers and computational scoring for coronary artery disease and smoking status | — |
| 4 | Pelikan Technologies Top kimono buying sites comparison, reviews, and rankings | $183M | 208 mo ago | — | 2001 | Dirk Boecker CEO | 232 patents Point‑of‑care blood sampling and micro‑injection devices for minimally invasive diagnostics | — |
| 5 | TrueBinding Developer of biotherapeutic solutions for cancer treatment | $170M | 44 mo ago | 89 | 2015 | — | 80 patents Therapeutic antibodies targeting Galectin‑3 and protein‑aggregation inhibition for disease treatment | — |
| 6 | OrsoBio Developer of therapeutics for multiple metabolic diseases | $152M | 15 mo ago | 10 | 2021 | — | 45 patents Small-molecule LXR modulators and ACMSD inhibitors for dyslipidemia and metabolic disease therapy | — |
| 7 | Forty Seven Developer of therapies for the treatment of a wide range of diseases | $150M | 82 mo ago | 7,128 | 2015 | — | 248 patents Bispecific antibody therapeutics targeting CD47/CD20 for hematologic cancers. | — |
| 8 | Bitterroot Bio Immunotherapy to develop and deliver medicines for cardiovascular disease | $145M | 36 mo ago | 12 12 → 29 (+142%) | 2021 | Irving Weissman Co-Founder | — | — |
| 9 | Exai Bio Developer of RNA biomarkers and AI platform for cancer detection | $138M | 21 mo ago | 47 | 2018 | Babak Alipanahi Co-Founder & Chief Scientific Officer | — | 1 job opening · 1 launch · 1 partnership |
| 10 | Immune-Onc Therapeutics Developer of antibodies to target immune system and tumor microenvironment | $138M | 41 mo ago | 24 24 → 12 (-50%) | 2016 | — | — | — |
| 11 | Affymax Drug for treatment of chronic kidney disease | $131M | 207 mo ago | 72 | 2001 | — | 162 patents Erythropoietin receptor agonist peptides and PEGylated peptide drug delivery technologies | — |
| 12 | Inceptive AI-based RNA molecular modeling tool for the vaccine | $120M | 33 mo ago | 35 | 2021 | Jakob Uszkoreit Co-Founder & CEO | — | 1 partnership |
| 13 | Pheast Developer of immunotherapeutics for cancer treatment | $101M | 43 mo ago | 20 | 2020 | Roy Maute Co-Founder | — | 1 launch · 1 award |
| 14 | Antheia Genetically engineered yeast cells to produce medicinal products 64Funding top 20%Patents top 25%Moat top 28%Innovation top 34% All 12 signals ▾Fundingtop 20% Patentstop 25% Moattop 28% Innovationtop 34% Producttop 35% Growthtop 36% Talenttop 40% Techtop 45% Newstop 45% Partnerstop 45% Globalbottom 47% Marketbottom 45% Funding: Raised $96.4M across 13 rounds · 13 rounds over 11 yrs (1.2/yr) Patents: 82 patents matched (strict assignee match) · 52 filings since 2022 vs 30 in 2017-21 rank vs industry peers · Fliar Intelligence Index 64/100 | $96M | 4 mo ago | 50 50 → 66 (+32%) | 2013 | Christina Smolke Co-Founder & CEO | 82 patents Biotechnological production and optimization of opioid alkaloids (benzylisoquinoline and morphinan) | 2 job openings |
| 15 | Anacor Pharmaceuticals Developer of small-molecule therapeutics for the treatment of infectious and autoimmune diseases | $90M | 122 mo ago | 110 | 2002 | — | 769 patents Oxaborole-based anti-inflammatory and antiparasitic drug compounds and formulations | — |
| 16 | Centrillion Technologies Developer of DNA chips and molecular assays | $87M | 95 mo ago | 23 | 2009 | — | 6 patents High-throughput DNA sequencing reagents, microarray fabrication, and surface-modified platforms | — |
| 17 | InCarda Therapeutics Developer of therapeutic solutions for acute cardiovascular symptoms | $80M | 67 mo ago | 30 | 2009 | Narsi Rangachari Co-Founder | — | — |
| 18 | Science Exchange Online marketplace for outsourcing scientific research | $78M | 80 mo ago | 39 | 2011 | Dan Knox Co-Founder & COO | — | — |
| 19 | Excellergy Developer of trifunctional effector cell response inhibitors for allergic diseases | $70M | 8 mo ago | — | 2020 | Theodore Jardetzky Co-Founder | 5 patents Therapeutic antibodies and fragments that bind IgE for allergy treatment | — |
| 20 | Comprehend Provider of cloud-based software for clinical operations teams | $66M | 87 mo ago | 2 | 2010 | — | — | — |
| 21 | Polares Medical Developer of medical devices for treating mitral valve regurgitation | $65M | 3 mo ago | 20 | 2010 | Jacques Essinger Founder & CEO | — | — |
| 22 | Eidos Therapeutics Developer of a small-molecule treatment solution for transthyretin amyloidosis | $64M | 98 mo ago | 70 | 2016 | Isabella Graef Co-Founder | — | — |
| 23 | Satiety Device for transoral gastroplasty, an endoscopic approach to satiety induction | $64M | 200 mo ago | 10 | 2000 | — | 80 patents Minimally invasive gastric volume-reduction and partitioning devices for obesity therapy. | — |
| 24 | Onera Developer of a wearable sleep monitoring system | $60M | 29 mo ago | 50 | 2018 | Pieter Ermers VP Research and Development & Founder | — | 1 partnership |
| 25 | Ancora Biotech Developer of Immunotherapeutics for B cell cancers, metabolic diseases, and chronic hepatitis B infections | $60M | 48 mo ago | 12 | 2021 | Ben Buelow CEO | — | — |
| 26 | Zenflow Developer of device to treat urinary obstruction related to BPH | $55M | 19 mo ago | 25 25 → 42 (+68%) | 2014 | Shreya Mehta ex-Co-Founder & CEO | 69 patents Precise implantation and imaging devices for prostatic urethra treatments | — |
| 27 | Endpoint Health Developer of precision therapeutics for immune-mediated diseases | $52M | 48 mo ago | 21 | 2018 | Jason Springs Co-Founder &CEO | — | — |
| 28 | Vibrynt Vibrynt: Stylish coat hooks and home storage solutions provider | $50M | 168 mo ago | — | 2006 | Beverly Huss President and CEO | 61 patents Minimally invasive gastric volume reduction devices for obesity treatment. | — |
| 29 | Kalaris Therapeutics Developer of therapeutics for retinal disorders | $50M | 6 mo ago | — | 2024 | Srinivas Akkaraju Co-Founder & Director | — | — |
| 30 | Vincerx Pharma Developer of cancer therapeutics | $50M | 57 mo ago | 43 | 2020 | — | — | — |
| 31 | Signostics Provider of POC ultrasound device to calculate bladder volume | $44M | 127 mo ago | 112 | 2005 | Stewart Bartlett Co-Founder & COO | — | — |
| 32 | Neuraltus Developing proprietary small molecule immunomodulator drugs for neurodegenerative diseases | $43M | 120 mo ago | 5 | 2009 | — | — | — |
| 33 | Carbylan Therapeutics using polymers of hyaluronic acid for pain management. | $43M | 135 mo ago | 7 | 2004 | — | — | — |
| 34 | Cellanome Developer of the omic data platform for researchers | $43M | 39 mo ago | — | 2020 | Mostafa Ronaghi Co-Founder | 77 patents Microfluidic platforms for cellular analysis, imaging, sorting, and multiplex assay screening | — |
| 35 | Neumentum Developing non-opioid pain management solutions for acute and chronic pain | $41M | 37 mo ago | 8 | 2017 | Joseph Pergolizzi Co-Founder | 5 patents Topical analgesic and anti-inflammatory pharmaceutical formulations | — |
| 36 | Overture Life Developer of embryology diagnosis device for professionals 67Patents top 26%AI top 28%Talent top 28%Funding top 29% All 11 signals ▾Patentstop 26% AItop 28% Talenttop 28% Fundingtop 29% Moattop 31% Innovationtop 32% Growthtop 35% Techbottom 44% Globalbottom 43% Marketbottom 37% Newsbottom 18% Patents: 44 patents matched (strict assignee match) · 34 filings since 2022 vs 10 in 2017-21 AI: Holds AI/ML patents (G06N-family CPC) · Product described with: ai powered rank vs industry peers · Fliar Intelligence Index 67/100 | $37M | 7 mo ago | 41 | 2017 | Jose Horcajadas Co-Founder & Chief Scientific Officer | 44 patents Automated microinjection and microfluidic handling for IVF and embryo selection | 1 launch · 1 partnership |
| 37 | N Focus Neuro Endovascular neurosurgery solutions for the treatment of intracranial aneurysms | $37M | 144 mo ago | 6 | 2007 | — | — | — |
| 38 | Kodiak Sciences Developer of therapeutics to treat retinal diseases | $36M | 97 mo ago | 112 112 → 138 (+23%) | 2009 | Victor Perlroth Chairman and CEO | 211 patents Antibody‑drug conjugates and protein therapeutics targeting cytokines and ocular disease. | — |
| 39 | OmniAb Therapeutic antibody discovery company providing diverse antibody repertoires and cutting-edge screening… 48Patents top 25%Innovation top 33%Funding top 36%Tech top 42% All 10 signals ▾Patentstop 25% Innovationtop 33% Fundingtop 36% Techtop 42% Markettop 46% Moattop 48% Globalbottom 38% Fin. healthbottom 38% Growthbottom 33% Newsbottom 18% Patents: 30 patents matched (strict assignee match) · 29 filings since 2022 vs 1 in 2017-21 Innovation: 30 patents (top 42% of patent-holders) · 29 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 48/100 | $30M | 9 mo ago | 95 | 2012 | — | 30 patents Therapeutic antibodies for immune checkpoints and viral targets, plus APOL1 small‑molecule inhibitors. | — |
| 40 | Mekonos Developer of silicon-based nanomachine chips | $30M | 55 mo ago | 48 | 2016 | Greg Sitters Co-Founder | 49 patents Patents concentrated in transport & manufacturing processes | — |
| 41 | Epalex Developer of therapies for treating neurological disorders | $26M | 7 mo ago | 2 | 2009 | Brendan Magrab CEO | 30 patents Prodrug and formulation technologies for intravenous anesthetic propofol delivery | — |
| 42 | Artificial Intelligence AI‑driven lab automation platform | $22M | 61 mo ago | 26 26 → 15 (-42%) | 2018 | David Fuller Chief Executive Officer | 97 patents Patents concentrated in computing, sensing & instrumentation | — |
| 43 | Pumpkinseed Developer of protein sequencing technology using silicon photonics and machine learning 67Talent top 35%Funding top 36%AI top 45%Global bottom 33% All 4 signals ▾Talenttop 35% Fundingtop 36% AItop 45% Globalbottom 33% Talent: 3 named leaders on record Funding: Raised $20.3M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) rank vs industry peers · Fliar Intelligence Index 67/100 | $20M | 1 mo ago | — | 2021 | Jennifer Dionne Co-Founder | — | — |
| 44 | GEn1E Developer of therapeutics for the treatment of inflammatory and rare diseases | $17M | 7 mo ago | 19 | 2018 | Ritu Lal Co-Founder & CEO | — | — |
| 45 | Surf Bio Developer of therapeutics for the treatment of multiple diseases | $16M | 25 mo ago | 4 | 2021 | Jennifer Schneider Md Founder | — | — |
| 46 | HUMA.AI AI-based business development tool for healthcare | $14M | 14 mo ago | 28 | 2018 | Lana Feng Co-Founder & CEO | — | 1 launch |
| 47 | Electron Optica Provider of solutions for electron microscopy and electron lithography 37Funding top 44%Talent bottom 45%Global bottom 29% All 3 signals ▾Fundingtop 44% Talentbottom 45% Globalbottom 29% Funding: Raised $9.3M across 8 rounds · 8 rounds over 15 yrs (0.5/yr) Talent: 1 named leader on record rank vs industry peers · Fliar Intelligence Index 37/100 | $9M | 14 mo ago | — | 2011 | Marian Mankos Founder & CEO | — | — |
| 48 | PhnyX Lab AI-powered solutions to simplify workflows in pharmaceutical research | $4M | 10 mo ago | — | 2024 | Harshit Gupta Co-Founder | — | — |
| 49 | Interface Biosciences Developer of microbiome therapeutics to treat inflammatory diseases | $3M | 30 mo ago | 7 | 2020 | — | — | — |
| 50 | Greenstone AI-based computational platform for drug discovery | $3M | 24 mo ago | 13 | 2021 | Joseph Wu Co-Founder | — | 2 partnerships |
Top 12 Life Sciences companies in Palo Alto
#1
Series C · Palo Alto, California · founded 2013 · 50 employees$96.4Mraised▾
Series C · Palo Alto, California · founded 2013 · 50 employees
Antheia is focused on developing medicines using its technology. Its technology combines synthetic biology, informatics, and fermentation technology to provide plant-based medicines. It is currently working on engineering the yeast cells genetically to produce natural medicinal products.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Funding
top 20%Patents
top 25%Moat
top 28%Innovation
top 34%Product
top 35%Growth
top 36%Funding: Raised $96.4M across 13 rounds · 13 rounds over 11 yrs (1.2/yr) · Last round Series C (Jan 2026)
Patents: 82 patents matched (strict assignee match) · 52 filings since 2022 vs 30 in 2017-21 · Latest publication 2025
Moat: Editorial + unicorn rating 8/10 · IP moat: 82 patents · Soonicorn
Audience (LinkedIn): 10k LinkedIn followers — 2.6% of this cohort's audience
Hiring (LinkedIn): 2 hiring posts in 12 mo (public) · momentum +2 · hiring: Associate Director of Global Quality, Senior Quality Control Manager
Funding rounds
- Jan 2026Series C$24M
- Jun 2025Series C$56M
- Jul 2024Series B$6M
- Jun 2022Venture Debt$40M
Founders & team
Investors
Viking Global Investors, Sherpalo Ventures, In-Q-Tel, Echo, Oxford Finance, SVB
Tech stack
BabelCloudflareCloudflare Bot ManagementCookieyesCore-JsElementor
#2
Series C · Palo Alto, California · founded 2010 · 20 employees$65Mraised▾
Series C · Palo Alto, California · founded 2010 · 20 employees
Developer of medical devices for treating mitral valve regurgitation. The company is developing a minimally-invasive trans-catheter hemi-replacement system, PLAR system, to treat insufficiency in the function of the mitral valve.
Funding rounds
- Mar 2026Series C$50M
- Jun 2020Series B$40M
- Jul 2018Series A$25M
Founders & team
Investors
Decheng Capital, Endeavour Vision, IDO Investments, Earlybird, Wellington Partners Venture Capital, Longitude Capital
#3
Series A · Palo Alto, California · founded 2021$20.3Mraised▾
Series A · Palo Alto, California · founded 2021
Developer of protein sequencing technology using silicon photonics and machine learning. The company focuses on high-resolution protein analysis, including sequence, post-translational modifications, structure, and interactions. It aims to provide insights into the proteome to address challenges in personal, population, and ecosystem health. The technology amplifies light to analyze proteins without relying on sample amplification or fluorescent tags. The goal is to enable proactive solutions in medicine and sustainability.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Talent
top 35%Funding
top 36%AI
top 45%Global
bottom 33%Talent: 3 named leaders on record
Funding: Raised $20.3M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) · Last round Series A (May 2026)
AI: Product described with: machine learning
Funding rounds
- May 2026Series A$20M
- Apr 2025Grant (prize money)$289.9K
Founders & team
Investors
HHS, NFX, Future Ventures, Base4 Capital, Analog Devices, Stanford University
#4
Late Stage · Palo Alto, California · founded 2024$50Mraised▾
Late Stage · Palo Alto, California · founded 2024
Developer of therapeutics for retinal disorders. It offers a lead product, TH103 which is a fully humanized, recombinant fusion protein designed for intravitreal delivery as anti-VEGF agent for the treatment of neovascular age-related macular degeneration.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 6k LinkedIn followers
Funding rounds
- Dec 2025Post IPO$50M
Founders & team
Investors
ADAR1, Coastlands Capital, RTW Investments, Samsara BioCapital, Woodline Partners, Invus
#5
Acquired · Palo Alto, California · founded 2020$70Mraised▾
Acquired · Palo Alto, California · founded 2020
Developer of trifunctional effector cell response inhibitors for allergic diseases. It focuses on advancing beyond traditional anti-IgE approaches. The company targets IgE bound to the effector cell, the source of allergic signaling. It aims to improve patient quality of life by combating severe allergic diseases.
Funding rounds
- Oct 2025Series A$70M
Founders & team
Investors
Samsara BioCapital, Red Tree Venture Capital, Decheng Capital
Tech stack
Anime.JsCloudflareCloudflare Browser InsightsCloudflare StreamCookieyesCore-Js
#6
Series C · Palo Alto, California · founded 2017 · 41 employees$37Mraised▾
Series C · Palo Alto, California · founded 2017 · 41 employees
Developer of embryology diagnosis device for professionals. It offers DaVitri an automated platform designed to modernize egg freezing and embryo warming workflows, automates critical timing and cryoprotectant exposure steps for improved consistency and oocyte survival rates. It also offers m|z test an AI powered metabolomic test designed for non-invasive embryo selection.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Patents
top 26%AI
top 28%Talent
top 28%Funding
top 29%Moat
top 31%Innovation
top 32%Patents: 44 patents matched (strict assignee match) · 34 filings since 2022 vs 10 in 2017-21 · Latest publication 2026
AI: Holds AI/ML patents (G06N-family CPC) · Product described with: ai powered
Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
Audience (LinkedIn): 12k LinkedIn followers — 3.1% of this cohort's audience
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. TekServis Ltd. ti.) announced in 12 mo
Funding rounds
- Nov 2025Conventional Debt$23M
- Apr 2025Series C$20.6M
- May 2021Series B$15M
- Dec 2018Series A$13.6M
Founders & team
Investors
Octopus Ventures, Google Ventures, Khosla Ventures, Felicis Ventures, Overwater Ventures, European Investment Bank
Tech stack
Amazon CloudfrontAmazon S3Amazon Web ServicesCdnjsCloudflareCloudflare Bot Management
#7
Series A · Palo Alto, California · founded 2009 · 2 employees$25.6Mraised▾
Series A · Palo Alto, California · founded 2009 · 2 employees
Developer of therapies for treating neurological disorders. The company is developing therapies for treating neurological disorders (migraine and epilepsy) in collaboration with the University of California. The lead candidate of the company, EP-102, is an oral treatment for acute migraine. It is a short-acting benzodiazepine and acts on gamma-aminobutyric acid (GABA) receptors.
Funding rounds
- Oct 2025Series A$1.2M
- Dec 2024Series A$4M
- Oct 2022Series A$4.3M
- Dec 2020Series A$20.3M
Founders & team
#8
Series B · Palo Alto, California · founded 2021 · 10 employees$151.6Mraised▾
Series B · Palo Alto, California · founded 2021 · 10 employees
Developer of therapeutics for multiple metabolic diseases. It offer drug cangidates that target central pathways of energy metabolism which include ACC2 inhibitor TLC-3595 for type-2 diabetes, LXR inverse agonist TLC-2716 for Severe Dyslipidemias, Mitochondrial protonophore TLC-6740, and TLC-1235 for Lipodystrophies.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Funding rounds
- Feb 2025Series B$1.7M
- Feb 2025Grant (prize money)$2.3M
- Aug 2024Series B$67M
- Oct 2023Series A$84.6M
Investors
Longitude Capital, Enavate Sciences, Samsara BioCapital, NuevaBio, Lilly, Ascenta Capital
#9
Series A · Palo Alto, California · founded 2018 · 19 employees$17.2Mraised▾
Series A · Palo Alto, California · founded 2018 · 19 employees
Developer of therapeutics for the treatment of inflammatory and rare diseases. The company's platform is utilizing the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform to create novel therapies for rare and inflammatory diseases. The lead candidate molecule is "GEn-1124"- for lung chronic conditions and other candidate molecules are in the research and discovery phase.
Funding rounds
- Oct 2025Series A$5.5M
- Dec 2022Series A$17M
- 2021Seed—
- Aug 2019Seed$125K
Founders & team
Investors
Clear Ventures, Y Combinator, SV Latam Capital, Khosla Ventures, Neue Fund, Harmonix
#10
Public · Palo Alto, California · founded 2012 · 95 employees$30Mraised▾
Public · Palo Alto, California · founded 2012 · 95 employees
Therapeutic antibody discovery company providing diverse antibody repertoires and cutting-edge screening technologies. They empower pharmaceutical partners with access to advanced antibody discovery platforms for next-generation therapeutics. They offer validated transgenic animals capable of generating high-quality, fully human antibodies. Their technology includes heavy chain-only transgenic chicken for diverse antibody repertoires. They provide antibody generation, antigen design, bispecific platforms, xPloration screening, and antibody optimization services. They also offer Fc-silencing, ion channel, transporter, and in silico technologies. They focus on partnerships to advance clinical drug development. They provide antibody discovery services.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Patents
top 25%Innovation
top 33%Funding
top 36%Tech
top 42%Market
top 46%Moat
top 48%Patents: 30 patents matched (strict assignee match) · 29 filings since 2022 vs 1 in 2017-21 · Latest publication 2026
Innovation: 30 patents (top 42% of patent-holders) · 29 filings since 2022 vs 1 in 2017-21
Funding: Raised $30.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Post IPO (Aug 2025)
Funding rounds
- Aug 2025Post IPO$30M
Tech stack
Apple Icloud MailAstraCallrailCloudflareCloudflare Bot ManagementCloudflare Browser Insights
#11
Series B · Palo Alto, California · founded 2018 · 47 employees$138.1Mraised▾
Series B · Palo Alto, California · founded 2018 · 47 employees
Developer of RNA biomarkers and AI platform for cancer detection. It focuses on identifying signals from RNA to gain clinical insights. The platform aims to revolutionize cancer diagnosis, treatment, and management. It utilizes novel RNA biomarkers and artificial intelligence to connect previously unseen clinical insights.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 6k LinkedIn followers
Hiring: 1 hiring post in 12 mo (public)
Activity: 2 product launches · 1 partnerships (incl. Deviation Capital) announced in 12 mo
Funding rounds
- Sep 2024Grant (prize money)$1.3M
- Oct 2022Series B$70.6M
- Dec 2021Series A$67.5M
Founders & team
Investors
Casdin Capital, Two Sigma Ventures, S32, HHS, BVF
#12
Acquired · Palo Alto, California · founded 2015 · 383 employees$434.2Mraised▾
Acquired · Palo Alto, California · founded 2015 · 383 employees
Developer of therapeutics for the treatment of genetic diseases. It utilizes a mapping of various genetic disease landscapes to identify opportunities for therapeutic intervention. The company's drug candidates include PTCH1-inhibitor for Gorlin syndrome and S1P-lyase inhibitor for Darier disease and Hailey-Hailey disease and others.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 81k LinkedIn followers — 21.0% of this cohort's audience
Activity: 1 awards announced in 12 mo
Funding rounds
- Apr 2024Post IPO$200M
- Feb 2021Post IPO$4.5M
- Jan 2021Post IPO$650M
- Jan 2019Series D$299.2M
Founders & team
Investors
KKR, Viking Global Investors, Perceptive Advisors, AIG, Hercules Capital, Aisling Capital
Tech stack
Amazon CloudfrontAmazon Web ServicesApple Icloud MailCloudflareCloudflare Bot ManagementContentful
Funding & investor landscape
$4.7Btotal disclosed funding
96companies funded
293disclosed rounds
1rounds last 90 days
Most active investors
Y Combinator7 rounds
Notable founders
Christina Smolke
Co-Founder & CEO · Antheia
Kristy Hawkins
Co-Founder & CSO · Antheia
Jacques Essinger
Founder & CEO · Polares Medical
Jennifer Dionne
Co-Founder · Pumpkinseed
Jack Hu
Co-Founder · Pumpkinseed
Srinivas Akkaraju
Co-Founder & Director · Kalaris Therapeutics
Napoleone Ferrara
Co-Founder · Kalaris Therapeutics
Theodore Jardetzky
Co-Founder · Excellergy
Alexander Eggel
Co-Founder · Excellergy
Jose Horcajadas
Co-Founder & Chief Scientific Officer · Overture Life
Santiago Munne
Co-Founder & CIO · Overture Life
Brendan Magrab
CEO · Epalex
Prism market signals · United States · country-scoped Prism corpus, 1,465,538 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
research sentiment over time
200820162026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and steady — the enthusiastic (strongly-positive) share moved 44% → 42% across 2008–2026.
top research entities
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
leading researchers
Stylianos Chatzimanolis · TARIK DEDOVIC · KATH-RYN ANN F. HANKINS · Christoforos Pavlou · Giannis Bolanakis · Ashley R Tetens · Tyler Findlay · Jordyn Craig-Schwartz
▲
Breakthroughs2,038 · 33%
▼ 41%→30% share
▼0.7× share momentum0 median citations71% since 2021mostly empirical
Gene-focused breakthrough research is surging — papers rose from 33 to 164 while three sub-topics including Identification and Reporter gene emerged brand-new.
rising sub-themes (early→recent)
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
Newly emergingIdentification (biology) 0→18 · Function (biology) 0→18 · Reporter gene 0→16
Landmark U1 snRNP regulates cancer cell migration and invasion in vitro · 7,224 cites
◆
Advancements2,118 · 34%
▲ 29%→35% share
▲1.2× share momentum0 median citations80% since 2021mostly empirical
Cell culture and fermentation advancements are intensifying — papers jumped from 3→62 and 2→54 respectively as Advancements field-share grew to 35%.
rising sub-themes (early→recent)
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
Newly emergingIdentification (biology) 0→27 · Probiotic 0→24 · Cultivar 0→23
Landmark Using Deep Learning for Image-Based Plant Disease Detection · 4,262 cites
▼
Concerns1,006 · 16%
▼ 17%→15% share
▼0.9× share momentum0 median citations73% since 2021mostly empirical
Antibiotic resistance concern is escalating — papers tripled from 15 to 45 alongside newly emerging Animal health and Integrated pest management signals.
rising sub-themes (early→recent)
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Newly emergingQuality (philosophy) 0→27 · Animal health 0→14 · Integrated pest management 0→13
Landmark The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate · 8,812 cites
RESEARCH HOTSPOTS · United States
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston351 · +0.52
New York319 · +0.47
SF Bay Area235 · +0.57
Philadelphia115 · +0.60
San Diego101 · +0.59
Seattle95 · +0.46
Chicago95 · +0.57
Los Angeles93 · +0.61
Pittsburgh65 · +0.54
Ann Arbor65 · +0.58
PATENT SIGNAL · United States
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
457,918 filings8,000 assigneespeak 51616/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Genentech18103
- UNIV California17969
- Regeneron Pharma16083
- Amgen10510
- Monsanto Technology9754
- UNIV Pennsylvania8526
- Harvard College7463
- UNIV Texas7382
Common questions
How many Life Sciences companies are there in Palo Alto, United States?
Radar tracks 165 indexable Life Sciences companies headquartered in Palo Alto, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Palo Alto, United States?
The Life Sciences companies in Palo Alto, United States on this list have raised a combined $4.7B in disclosed equity funding across 96 funded companies.
Which is the highest-funded Life Sciences company in Palo Alto, United States?
Medable is the highest-funded Life Sciences company in Palo Alto, United States, with $521M in disclosed equity funding.
How many Life Sciences companies in Palo Alto, United States are funded?
96 of the 165 Life Sciences companies in Palo Alto, United States on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Palo Alto, United States?
1 Life Sciences company in Palo Alto, United States on this list is valued at $1B or more.
Who are the top investors in Palo Alto, United States Life Sciences companies?
The most active investors in Palo Alto, United States Life Sciences companies on this list include HHS, Y Combinator, Alta Partners, Andreessen Horowitz, Arch Venture Partners.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.